Sistema de Salut de Catalunya
Institut Català de la Salut
[Vivanco-Hidalgo RM, Martinez E, Roman-Viñas R] Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut Generalitat de Catalunya, Carrer de Roc Boronat 81-95, Barcelona, Spain. [Molina I, Sánchez-Montalvá A] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fibla J] Unitat de Genètica Humana, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Av. Alcalde Rovira Roure, 80, Lleida, Spain. Institut de Recerca Biomedica de Lleida, Av. Alcalde Rovira Roure, 80, Lleida, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-07-19T12:58:51Z
2021-07-19T12:58:51Z
2021-03-04
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cloroquina; Hidroxicloroquina
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cloroquina; Hidroxicloroquina
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Chloroquine; Hydroxychloroquine
Background Several clinical trials have assessed the protective potential of chloroquine and hydroxychloroquine. Chronic exposure to such drugs might lower the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or severe coronavirus disease (COVID-19). Aim To assess COVID-19 incidence and risk of hospitalisation in a cohort of patients chronically taking chloroquine/hydroxychloroquine. Methods We used linked health administration databases to follow a cohort of patients with chronic prescription of hydroxychloroquine/chloroquine and a control cohort matched by age, sex and primary care service area, between 1 January and 30 April 2020. COVID-19 cases were identified using International Classification of Diseases 10 codes. Results We analysed a cohort of 6,746 patients (80% female) with active prescriptions for hydroxychloroquine/chloroquine, and 13,492 controls. During follow-up, there were 97 (1.4%) COVID-19 cases in the exposed cohort and 183 (1.4%) among controls. The incidence rate was very similar between the two groups (12.05 vs 11.35 cases/100,000 person-days). The exposed cohort was not at lower risk of infection compared with controls (hazard ratio (HR): 1.08; 95% confidence interval (CI): 0.83–1.44; p = 0.50). Forty cases (0.6%) were admitted to hospital in the exposed cohort and 50 (0.4%) in the control cohort, suggesting a higher hospitalisation rate in the former, though differences were not confirmed after adjustment (HR: 1·46; 95% CI: 0.91–2.34; p = 0.10). Conclusions Patients chronically exposed to chloroquine/hydroxychloroquine did not differ in risk of COVID-19 nor hospitalisation, compared with controls. As controls were mainly female, findings might not be generalisable to a male population.
No funding was obtained for this study. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.
Article
Published version
English
COVID-19 (Malaltia) - Catalunya; Medicaments antivírics - Efectes secundaris; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents; Other subheadings::Other subheadings::Other subheadings::/adverse effects; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::morbilidad::incidencia; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
European Centre for Disease Prevention and Control
Eurosurveillance;26(9)
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.9.2001202
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
